Active Ingredient History
Varenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain. Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectiviyty for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms. Varenicline is sold under the trade name Chantix and Champix, it is indicated for use as an aid to smoking cessation treatment. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Smoking (approved 2006)
Acute Coronary Syndrome (Phase 4)
Alcohol Drinking (Phase 4)
Alcohol-Induced Disorders (Phase 2/Phase 3)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 2)
Amphetamine-Related Disorders (Phase 1)
Asthma (Phase 4)
Behavior, Addictive (Phase 4)
Biological Availability (Phase 1)
Bipolar Disorder (Phase 4)
Cannabis (Phase 2)
Carcinoma (Phase 4)
Chronic Pain (Phase 1)
Cigarette Smoking (Phase 4)
Cocaine-Related Disorders (Phase 2)
Cognition (Phase 1)
Community-Acquired Infections (Phase 4)
Comorbidity (Phase 4)
Corneal Diseases (Phase 2)
Coronary Disease (Phase 4)
Craving (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Dopamine (Phase 1)
Dry Eye Syndromes (Phase 4)
Electronic Nicotine Delivery Systems (Phase 4)
Friedreich Ataxia (Phase 2/Phase 3)
Habits (Phase 2/Phase 3)
Harm Reduction (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
HIV (Phase 4)
HIV Infections (Phase 4)
Hypertension (Phase 4)
Lung Neoplasms (Phase 3)
Machado-Joseph Disease (Phase 2)
Marijuana Abuse (Phase 4)
Medication Adherence (Phase 4)
Mental Disorders (Phase 4)
Methadone (Phase 4)
Methamphetamine (Phase 2)
Nausea (Phase 4)
Neoplasms, Second Primary (Phase 2)
Nicotine (Phase 4)
Obesity (Phase 2/Phase 3)
Opioid-Related Disorders (Phase 4)
Pain (Phase 4)
Parkinson Disease (Phase 4)
Parkinsonian Disorders (Phase 4)
Pharmacokinetics (Phase 1)
Psychological Distress (Phase 4)
Psychotic Disorders (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Recurrence (Phase 4)
Schizophrenia (Phase 4)
Sjogren's Syndrome (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Smoking (Phase 4)
Smoking Cessation (Phase 4)
Smoking Reduction (Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Substance-Related Disorders (Phase 4)
Substance Withdrawal Syndrome (Phase 4)
Tardive Dyskinesia (Phase 4)
Tobacco (Phase 2/Phase 3)
Tobacco Smoking (Phase 4)
Tobacco Use (Phase 3)
Tobacco Use Cessation (Phase 4)
Vaping (Phase 4)
Weight Gain (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
